These people are revolting. How many other crimes have they committed in support of their Pharma masters? A prominent Harvard Medical School professor has resigned from a U.S. Food and Drug Administration advisory panel in protest over the agency’s decision to approve Biogen Inc.’s Alzheimer’s drug Aduhelm. The doctor, Aaron Kesselheim, announced his departure in a letter to FDA Acting Commissioner Janet Woodcock. He is the third committee member to quit in the wake of the highly controversial approval. The clearance “was probably the worst drug approval decision in recent U.S. history,” Kesselheim said in the letter. Evidence that the drug works is mixed. Two big clinical trials produced conflicting results on whether it could slow cognitive decline, leading the advisory panel Kesselheim served on to urge the FDA not to let it on the market without further study. The agency elected to give the treatment a conditional approval on the basis that it could remove a bad protein called amyloid from the brain. Biogen must conduct an additional trial to confirm the drug’s effectiveness, the FDA said. The drug’s clearance was celebrated as a landmark by Alzheimer’s patients and many doctors. It was the first therapy for the brain-wasting disease to be approved in roughly two decades, and it is likely to be a blockbuster for Biogen and its partner, Tokyo-based Eisai Co. At a meeting in November, the advisory panel voted 8 to 1, with 2 undecided, that data from a single clinical trial with positive results was insufficient to show Biogen’s drug works. They also voted 10 to 0, with 1 undecided, that the positive study shouldn’t be considered primary proof the drug works in light of conflicting evidence from a different trial. Advertisement Article content “The agency owes it to the nation to provide a detailed justification” for going against the advice of the panel, Kesselheim said.